KEAP1 and non-small cell lung carcinoma: Therefore, when two or more gene mutations of KEAP1, STK11, PBRM1 and SMARCA4 coexist in NSCLC patients, especially in LUAD patients, it is still necessary to use immunotherapy with caution.